Maternal complications and preg- nancy outcome in women with mechanical prosthetic heart valves treated with enoxaparin. BJOG. 2009;116:1585 92. 40. Sillesen M, Hjortdal V, Vejlstrup N, et al. Pregnancy with prosthetic heart valves 30 years nationwide experience in Denmark. Eur J Cardiothorac Surg. 2011;40:448 54. 41. James AH, Brancazio LR, Gehrig TR, et al. Low-molecular-weight heparin for thromboprophylaxis in pregnant women with mechanical heart valves. J Matern Fetal Neonatal Med. 2006;19:543 9. heparin to prevent thromboembolic phenomena in pregnant patients with mechanical cardiac valve prostheses. J Am Coll Cardiol. 1996;27:1698 703. 43. Sbarouni E, Oakley CM. Outcome of pregnancy in women with valve pros- theses. Br Heart J. 1994;71:196 201. 44. Ozkan M, Cakal B, Karakoyun S, et al. Thrombolytic therapy for the treatment of prosthetic heart valve thrombosis in pregnancy with low- dose, slow infusion of tissue-type plasminogen activator. Circulation. 2013;128:532 40. 45. Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran ver- sus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369:1206 14. 14. SURGICAL CONSIDERATIONS 14.1. Evaluation and Management of CAD in Patients With VHD 14.1.1. Management of CAD in Patients Undergoing TAVI 1. Bajaj A, Pancholy S, Sethi A, et al. Safety and feasibility of PCI in patients undergoing TAVR: a systematic review and meta-analysis. Heart Lung. 2017;46:92 9. 2. Chakravarty T, Sharma R, Abramowitz Y, et al. Outcomes in patients with transcatheter aortic valve replacement and left main stenting: the TAVR- LM registry. J Am Coll Cardiol. 2016;67:951 60. 3. Mohr FW, Morice M-C, Kappetein AP, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three- vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet. 2013;381:629 38. 4. Thalji NM, Suri RM, Daly RC, et al. 